Pacific Biosciences (PACB) saw its stock soar 8.04% on Tuesday's trading session, driven by positive analyst ratings and price target updates.
Stephens & Co. maintained a $2.50 price target on PACB, expressing confidence in the company's prospects. Meanwhile, Morgan Stanley reiterated a "Hold" rating on the stock, setting a $2.00 price target.
The updates from these analysts reflect optimism surrounding Pacific Biosciences' future performance, boosting investor sentiment and driving the stock's significant upward movement during Tuesday's trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.